Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Xeris Biopharma Holdings (XERS) EBT Margin (2020 - 2025)

Xeris Biopharma Holdings (XERS) has disclosed EBT Margin for 6 consecutive years, with 12.91% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBT Margin rose 2142.0% year-over-year to 12.91%, compared with a TTM value of 0.19% through Dec 2025, up 2831.0%, and an annual FY2025 reading of 0.19%, up 2831.0% over the prior year.
  • EBT Margin was 12.91% for Q4 2025 at Xeris Biopharma Holdings, up from 0.83% in the prior quarter.
  • Across five years, EBT Margin topped out at 12.91% in Q4 2025 and bottomed at 308.95% in Q2 2021.
  • Average EBT Margin over 5 years is 83.09%, with a median of 42.99% recorded in 2022.
  • The sharpest move saw EBT Margin crashed -6418bps in 2021, then soared 20414bps in 2022.
  • Year by year, EBT Margin stood at 234.16% in 2021, then surged by 83bps to 40.03% in 2022, then rose by 23bps to 30.7% in 2023, then skyrocketed by 72bps to 8.51% in 2024, then soared by 252bps to 12.91% in 2025.
  • Business Quant data shows EBT Margin for XERS at 12.91% in Q4 2025, 0.83% in Q3 2025, and 2.7% in Q2 2025.